| Patricia L Palmer, CRNA | |
|
299 Kings Daughters Dr, Frankfort, KY 40601-6514 | |
| (502) 875-5240 | |
| Not Available |
| Full Name | Patricia L Palmer |
|---|---|
| Gender | Female |
| Speciality | Certified Registered Nurse Anesthetist (crna) |
| Experience | 39 Years |
| Location | 299 Kings Daughters Dr, Frankfort, Kentucky |
| Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1700876984 | NPI | - | NPPES |
| 0968645 | Medicaid | OH | |
| 74438359 | Medicaid | KY |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 367500000X | Nurse Anesthetist, Certified Registered | 196460 (Ohio) | Secondary |
| 367500000X | Nurse Anesthetist, Certified Registered | 3002726 (Kentucky) | Primary |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Anesthesia Dynamics Llc | 3779832530 | 363 |
| Ams National Llc | 3870813025 | 203 |
News Archive
NAADAC, the Association for Addiction Professionals, and Hazelden, the national nonprofit focused on addiction treatment, prevention and recovery announced today a new strategic partnership focused on improving the treatment of co-occurring disorders. The partnership announcement was made by NAADAC Executive Director Cynthia Moreno Tuohy during the National Conference on Addiction Disorders in Washington, D.C.
Millipore Corporation, a leading provider of technologies, tools and services for the global life science industry, today announced that its shareholders voted at a Special Meeting of Shareholders to approve the previously-announced acquisition of all outstanding shares of common stock of Millipore by Merck KGaA of Germany, the global pharmaceutical and chemical company.
Health and Human Services Secretary Kathleen Sebelius went to Florida Friday in her campaign to rally support for the new health law. She targeted senior citizens, a crucial voting bloc that polls find is not warming to the bill.
BiondVax Pharmaceuticals Ltd. announced today that it received regulatory clearance from the Hungarian Regulatory Authority (National Institute of Pharmacology and Nutrition, OGYEI) and the Central Ethics Committee in Budapest to initiate a Phase IIb clinical trial. The initiation meeting was scheduled for today, September 30, 2015, together with the partners from the UNISEC European Consortium.
Portola Pharmaceuticals, Inc., Bristol-Myers Squibb Company and Pfizer Inc. today announced a clinical collaboration agreement to conduct a proof-of-concept study of PRT4445 and the investigational oral Factor Xa inhibitor ELIQUIS (apixaban).
› Verified 3 days ago
| Entity Name | Fleming Island Anesthesia Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1487945895 PECOS PAC ID: 6002084860 Enrollment ID: O20110721000345 |
News Archive
NAADAC, the Association for Addiction Professionals, and Hazelden, the national nonprofit focused on addiction treatment, prevention and recovery announced today a new strategic partnership focused on improving the treatment of co-occurring disorders. The partnership announcement was made by NAADAC Executive Director Cynthia Moreno Tuohy during the National Conference on Addiction Disorders in Washington, D.C.
Millipore Corporation, a leading provider of technologies, tools and services for the global life science industry, today announced that its shareholders voted at a Special Meeting of Shareholders to approve the previously-announced acquisition of all outstanding shares of common stock of Millipore by Merck KGaA of Germany, the global pharmaceutical and chemical company.
Health and Human Services Secretary Kathleen Sebelius went to Florida Friday in her campaign to rally support for the new health law. She targeted senior citizens, a crucial voting bloc that polls find is not warming to the bill.
BiondVax Pharmaceuticals Ltd. announced today that it received regulatory clearance from the Hungarian Regulatory Authority (National Institute of Pharmacology and Nutrition, OGYEI) and the Central Ethics Committee in Budapest to initiate a Phase IIb clinical trial. The initiation meeting was scheduled for today, September 30, 2015, together with the partners from the UNISEC European Consortium.
Portola Pharmaceuticals, Inc., Bristol-Myers Squibb Company and Pfizer Inc. today announced a clinical collaboration agreement to conduct a proof-of-concept study of PRT4445 and the investigational oral Factor Xa inhibitor ELIQUIS (apixaban).
› Verified 3 days ago
| Entity Name | Ams National Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1316330830 PECOS PAC ID: 3870813025 Enrollment ID: O20150529000613 |
News Archive
NAADAC, the Association for Addiction Professionals, and Hazelden, the national nonprofit focused on addiction treatment, prevention and recovery announced today a new strategic partnership focused on improving the treatment of co-occurring disorders. The partnership announcement was made by NAADAC Executive Director Cynthia Moreno Tuohy during the National Conference on Addiction Disorders in Washington, D.C.
Millipore Corporation, a leading provider of technologies, tools and services for the global life science industry, today announced that its shareholders voted at a Special Meeting of Shareholders to approve the previously-announced acquisition of all outstanding shares of common stock of Millipore by Merck KGaA of Germany, the global pharmaceutical and chemical company.
Health and Human Services Secretary Kathleen Sebelius went to Florida Friday in her campaign to rally support for the new health law. She targeted senior citizens, a crucial voting bloc that polls find is not warming to the bill.
BiondVax Pharmaceuticals Ltd. announced today that it received regulatory clearance from the Hungarian Regulatory Authority (National Institute of Pharmacology and Nutrition, OGYEI) and the Central Ethics Committee in Budapest to initiate a Phase IIb clinical trial. The initiation meeting was scheduled for today, September 30, 2015, together with the partners from the UNISEC European Consortium.
Portola Pharmaceuticals, Inc., Bristol-Myers Squibb Company and Pfizer Inc. today announced a clinical collaboration agreement to conduct a proof-of-concept study of PRT4445 and the investigational oral Factor Xa inhibitor ELIQUIS (apixaban).
› Verified 3 days ago
| Entity Name | Crystal River Anesthesia Associates Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1437718392 PECOS PAC ID: 1951639715 Enrollment ID: O20190819001462 |
News Archive
NAADAC, the Association for Addiction Professionals, and Hazelden, the national nonprofit focused on addiction treatment, prevention and recovery announced today a new strategic partnership focused on improving the treatment of co-occurring disorders. The partnership announcement was made by NAADAC Executive Director Cynthia Moreno Tuohy during the National Conference on Addiction Disorders in Washington, D.C.
Millipore Corporation, a leading provider of technologies, tools and services for the global life science industry, today announced that its shareholders voted at a Special Meeting of Shareholders to approve the previously-announced acquisition of all outstanding shares of common stock of Millipore by Merck KGaA of Germany, the global pharmaceutical and chemical company.
Health and Human Services Secretary Kathleen Sebelius went to Florida Friday in her campaign to rally support for the new health law. She targeted senior citizens, a crucial voting bloc that polls find is not warming to the bill.
BiondVax Pharmaceuticals Ltd. announced today that it received regulatory clearance from the Hungarian Regulatory Authority (National Institute of Pharmacology and Nutrition, OGYEI) and the Central Ethics Committee in Budapest to initiate a Phase IIb clinical trial. The initiation meeting was scheduled for today, September 30, 2015, together with the partners from the UNISEC European Consortium.
Portola Pharmaceuticals, Inc., Bristol-Myers Squibb Company and Pfizer Inc. today announced a clinical collaboration agreement to conduct a proof-of-concept study of PRT4445 and the investigational oral Factor Xa inhibitor ELIQUIS (apixaban).
› Verified 3 days ago
| Entity Name | Anesthesia Dynamics Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1073001012 PECOS PAC ID: 3779832530 Enrollment ID: O20190820001117 |
News Archive
NAADAC, the Association for Addiction Professionals, and Hazelden, the national nonprofit focused on addiction treatment, prevention and recovery announced today a new strategic partnership focused on improving the treatment of co-occurring disorders. The partnership announcement was made by NAADAC Executive Director Cynthia Moreno Tuohy during the National Conference on Addiction Disorders in Washington, D.C.
Millipore Corporation, a leading provider of technologies, tools and services for the global life science industry, today announced that its shareholders voted at a Special Meeting of Shareholders to approve the previously-announced acquisition of all outstanding shares of common stock of Millipore by Merck KGaA of Germany, the global pharmaceutical and chemical company.
Health and Human Services Secretary Kathleen Sebelius went to Florida Friday in her campaign to rally support for the new health law. She targeted senior citizens, a crucial voting bloc that polls find is not warming to the bill.
BiondVax Pharmaceuticals Ltd. announced today that it received regulatory clearance from the Hungarian Regulatory Authority (National Institute of Pharmacology and Nutrition, OGYEI) and the Central Ethics Committee in Budapest to initiate a Phase IIb clinical trial. The initiation meeting was scheduled for today, September 30, 2015, together with the partners from the UNISEC European Consortium.
Portola Pharmaceuticals, Inc., Bristol-Myers Squibb Company and Pfizer Inc. today announced a clinical collaboration agreement to conduct a proof-of-concept study of PRT4445 and the investigational oral Factor Xa inhibitor ELIQUIS (apixaban).
› Verified 3 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Patricia L Palmer, CRNA 315 Morehead Dr, Frankfort, KY 40601-8623 Ph: (505) 848-0084 | Patricia L Palmer, CRNA 299 Kings Daughters Dr, Frankfort, KY 40601-6514 Ph: (502) 875-5240 |
News Archive
NAADAC, the Association for Addiction Professionals, and Hazelden, the national nonprofit focused on addiction treatment, prevention and recovery announced today a new strategic partnership focused on improving the treatment of co-occurring disorders. The partnership announcement was made by NAADAC Executive Director Cynthia Moreno Tuohy during the National Conference on Addiction Disorders in Washington, D.C.
Millipore Corporation, a leading provider of technologies, tools and services for the global life science industry, today announced that its shareholders voted at a Special Meeting of Shareholders to approve the previously-announced acquisition of all outstanding shares of common stock of Millipore by Merck KGaA of Germany, the global pharmaceutical and chemical company.
Health and Human Services Secretary Kathleen Sebelius went to Florida Friday in her campaign to rally support for the new health law. She targeted senior citizens, a crucial voting bloc that polls find is not warming to the bill.
BiondVax Pharmaceuticals Ltd. announced today that it received regulatory clearance from the Hungarian Regulatory Authority (National Institute of Pharmacology and Nutrition, OGYEI) and the Central Ethics Committee in Budapest to initiate a Phase IIb clinical trial. The initiation meeting was scheduled for today, September 30, 2015, together with the partners from the UNISEC European Consortium.
Portola Pharmaceuticals, Inc., Bristol-Myers Squibb Company and Pfizer Inc. today announced a clinical collaboration agreement to conduct a proof-of-concept study of PRT4445 and the investigational oral Factor Xa inhibitor ELIQUIS (apixaban).
› Verified 3 days ago
Richard V Brunner, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 299 Kings Daughter Drive, Frankfort, KY 40601 Phone: 502-875-5240 | |
Gina Barker, CRNA Nurse Anesthetist - CR Medicare: Medicare Enrolled Practice Location: 299 Kings Daughter Drive, Frankfort, KY 40601 Phone: 502-875-5240 | |
Bradford Shelby, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 299 Kings Daughters Dr, Frankfort, KY 40601 Phone: 502-875-5240 | |
Constance Wilson, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 299 Kings Daughter Drive, Frankfort, KY 40601 Phone: 502-875-5240 | |
Brandon R Cook I, CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 299 Kings Daughters Dr, Frankfort, KY 40601 Phone: 502-875-5240 | |
William Mccall, CRNA Nurse Anesthetist - CR Medicare: Not Enrolled in Medicare Practice Location: 299 Kings Daughters Dr, Frankfort, KY 40601 Phone: 502-875-5240 | |
Robert L Kipp Jr., CRNA Nurse Anesthetist - CR Medicare: Accepting Medicare Assignments Practice Location: 299 Kings Daughters Dr, Frankfort, KY 40601 Phone: 859-268-1030 Fax: 859-268-4120 |